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INTRODUCTION
 Marketing professionals increasingly encouraged 
to broaden their research into more non-
traditional areas such as modelling and 
forecasting
 Brodie & McIntyre (1987)
 Armstrong et al (1987)
RESEARCH PROJECT - AIMS
 Aims
1. To classify the patterns that are exhibited during the 
product lifecycle of pharmaceutical drugs
2. Model these patterns 
3. Forecast the patterns at different points throughout the 
lifecycle of the drug
4. This will allow us to discover which forecasting methods 
forecast the lifecycle better depending on the different 
stages
1. Introduction
2. Growth
3. Maturity
4. Decline
PHARMACEUTICAL MARKET
 Moss (2008) states that research has focused on 
consumer products and brands disregarding 
other products and brands such as 
pharmaceuticals. 
 In 2007 the top 10 pharmaceutical companies 
had a combined sales of just under £150 billion 
and commanded 45% market share
 2 of these were UK companies – AstraZeneca and 
GlaxoSmithKline
PHARMACEUTICAL MARKET CONTINUED
 In 2008 £4 billion was spent on R&D however 
this was expected to decrease due to the financial 
climate
 Patent Expiration – Major Problem
 UK patents last for 20 years from application
 5 year extension can be applied for
 Generics enter the market
PHARMACEUTICAL MARKET CONTINUED
 A branded drug is one made by a specific 
pharmaceutical company and is therefore given a 
name. The generic is the key compound that 
makes up the drug. In some cases the company 
can market both the branded and generic to 
appeal to a wider audience. An example is 
Sertraline.
 Brand name – Lustral by Pfizer
 Generic name – Sertraline.
PREVIOUS RESEARCH – PRODUCT
LIFE CYCLE
RESEARCH PROJECT – THE DATA
 JIGSAW database
 Established in 1985 by ISIS research for the 
purposes of academic research
 Data from 1987 -2008
 2.57 million script records
 Self Report Questionnaires from GP’s
 Data is specifically relating to what drugs are 
prescribed
FORECASTING METHODS
 Time Series Analysis
 Diffusion Models
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PRELIMINARY RESULTS
 All the graphs show that different prescription 
drugs have differing life cycles.
 Branded 1st – Generic 2nd Cross over
CONCLUSIONS
 There are a number of different types of lifecycle 
that occur in the pharmaceutical market
 They can be modelled and forecasted
 The research will make contributions to:
 The pharmaceutical industry
 Modelling and forecasting research
 The product lifecycle
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